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Introduction 28
The antibiotic resistance crisis has led to the search for alternative ways to treat 29 bacterial infections. One of the most promising forms of novel treatment strategies is to 30 modify the commensal microbiome in order to either prevent pathogen colonisation or 31 remove the pathogen once it has colonised 9 . The central idea behind this approach is to 32 introduce bacteria that can competitively suppress the pathogen. This strategy has 33 already demonstrated its promise with 'faecal transplant' therapies showing high 34 success rates in curing recurrent Clostridium difficile infections that are recalcitrant to 35 antibiotic treatment 1,2 . The remarkable success of microbiome manipulation in treating 36 C. difficile infections suggests that this approach may be viable as a treatment for other 37 infections, with suggestions that this approach could be used to prevent Staphylococcus 38 aureus nasal carriage 3,4 , to prevent dental caries 5 , and to prevent infections in plants to 39 improve crop yields 6, 7 . 40 While microbiome manipulation may at first appear to be a robust way to treat or 41 prevent infection, the amazing ability of bacterial pathogens to adapt to both antibiotic 42 treatments 10 and vaccines 11 shows that we must consider the evolutionary 43 consequences of any novel treatment strategies. So, how could pathogens evolve 44 resistance to microbiome manipulation? Overcoming competition from commensals is 45 not a new challenge for pathogens and they have evolved an array of weapons to help 46 them remove commensal competitors and colonise their host, either by directly killing 47 competitors or provoking host inflammation to which they are resistant 12--14 .
3 Importantly, these weapons are often direct causes of virulence in the host. Examples in 49 human pathogens include suicidal invasion of gut tissue in order to provoke 50 inflammation in Salmonella enterica serovar Typhimurium 15, 16 ; release of shiga toxin 51 encoding phage by shigatoxinagenic Escherichia coli, which removes competitors both 52 directly and via inflammation 13, 17 ; release of the toxin pyocyanin by Pseudomonas 53 aeruginosa 18, 19 ; provocation of host immune responses by Haemophilus influenzae 20 ; and 54 release of the toxin TcdA by C. difficile causing inflammation that may clear 55 commensals 16,21--23 . Increasing the strength of competition that these pathogens face 56 from commensals could create selection for increased expression of these weapons, 57 potentially leading to the evolution of increased virulence. Here we use a multi--level 58 model of both within--host competition between a pathogen and commensals and the 59 epidemiological spread of the pathogen to examine the evolutionary and 60 epidemiological consequences of the use of microbiome manipulation as a treatment 61 strategy. 62 63
Results and Discussion 64
We consider a scenario where a pathogen competes with an introduced therapeutic 65 commensal bacterium at the disease site ( Fig. 1a ). We assume for simplicity that both 66 species have the same basal per capita growth rate r (though relaxing this assumption 67 does not qualitatively affect our conclusions). The commensal competitor (at frequency 68 1 -P) reduces the growth rate of the pathogen by amount a(1 -P). The pathogen (at 69 frequency P) produces amount v of a virulence factor, which reduces the commensal's 70 growth rate (either directly or via interactions with the immune system) by amount bvP, 71
where b is the sensitivity of the commensal to the effects of the virulence factor. The 72 pathogen pays a growth rate cost c per unit virulence factor expression. Analysing this 73 system (see methods) we see that the pathogen free equilibrium (P = 0) is always locally 74 stable, while pathogen dominance (P = 1) is locally stable whenever b > c (i.e. as long as 75 commensal sensitivity to the virulence factor is greater than the cost of it's expression, 76 Fig. 1b ). There is also an internal unstable equilibrium (Fig. 1b) given by 77
If the frequency of the pathogen goes above this threshold then the pathogen 78 domination equilibrium is reached (P = 1), while if the pathogen frequency goes below 79 this threshold then the pathogen free equilibrium is reached (P = 0) ( Fig. 1b ). This 80 threshold will therefore decide how likely it is that a preventative treatment stops the 81 pathogen invading (stops transition from P = 0 to P = 1), and how likely it is for 82 responsive treatment to clear an infection (cause transition from P = 1 to P = 0). This 83 threshold pathogen frequency becomes higher (making it easier to clear the pathogen) 84 with increasing suppression by the commensal (a) and increasing costs of virulence 85 factor expression (c), while the threshold is lowered (making it more difficult to clear 86 the pathogen) by increasing sensitivity of the commensal (b) and increasing virulence 87 factor expression (v)( Fig. 1c ). 88
To model the evolutionary and epidemiological consequences of this competition 89 between pathogens and introduced commensals we use our within--host model to derive 90 an epidemiological model for the spread of strains with different levels of investment in 91 virulence factor production. Here we present a model for responsive treatment aimed at 92 clearing a pathogen once infection has been established (such as the case of faecal 93 transplant therapy in reponse to C. difficile infection), but we find qualitatively similar 94 results for a model of preventative treatment by modifying the microbiome of healthy 95 individuals (see supplementary information). The 'reproductive number' (number of 5 secondary infections caused when the pathogen is rare) of a pathogen strain of virulence 97 v is 98
where N, is the host population density, β is a transmission constant, γ is the baseline 99 clearance rate, δ is the baseline disease induced mortality, and τ is the treatment rate. 100
We can calculate the evolutionarily stable (ES) level of virulence factor production ( * ) 101 by maximising ! , giving
We can see from equation 3 that increasing rates of treatment with microbiome 103 manipulation (higher τ) select for increases in virulence factor production ( Fig. 2a ). 104
However, while microbiome manipulation increases selection for virulence factor 105 production, it simultaneously reduces the prevalence of the pathogen at equilibrium by 106 increasing the infection clearance rate, and can even lead to pathogen eradication at 107 high treatment rates ( Fig. 2b ). These conflicting effects of increasing pathogen virulence 108 and decreasing pathogen prevalence leads to a humped relationship between treatment 109 rate and the total disease induced mortality at equilibrium ( Fig. 2c ), meaning that 110 despite eradicating the pathogen at high treatment rates, microbiome manipulation can 111 actually lead to increased disease induced mortality if treatment is not sufficiently 112 aggressive. 113
Our analytical model assumes that the pathogen will evolve to its optimal level of 114 virulence factor production in the face of microbiome manipulation. However, if the 115 pathogen cannot evolve higher levels of virulence factor production quickly enough it 6 could be eradicated by treatment before it reaches its optimal virulence. To explore this 117 scenario we built a stochastic simulation model of the evolution of virulence factor 118 production under treatment with microbiome manipulation. Our simulations show that 119 the evolution of increased virulence factor production acts as a form of 'evolutionary 120 rescue' 24 for the pathogen -if the pathogen has a sufficiently high mutational supply it 121 can avoid eradication by evolving increased virulence (Fig. 3 ). This evolutionary rescue 122 becomes less likely with higher treatment rates as the pathogen population size declines 123 rapidly, reducing its mutational supply ( Fig. 3) . 124
If sufficiently high treatment intensity with microbiome manipulation cannot be 125 achieved pathogens can undergo evolutionary rescue via increased virulence factor 126 production, which can lead to increased disease induced mortality. However, 127 microbiome manipulation could be used with other co--therapies to increase its efficacy. 128
One approach that may allow sufficient increase in efficacy to avoid this outcome is to 129 combine microbiome manipulation with damage limitation therapies 8 . Damage 130 limitation therapies limit the pathogenesis of infection without directly killing 131 pathogens, by either inhibiting the production or action of pathogen virulence factors 132 (anti--virulence drugs 8,25 ), or by increasing the host's capacity to limit and repair tissue 133 damage from both the infection and its own immune response (pro--tolerance drugs 8,26 ). 134
These drugs thus will either directly inhibit the effects of the pathogen's virulence 135 factors (anti--virulence) or stop the induced inflammation (pro--tolerance), and could 136 therefore provide a powerful synergy with microbiome manipulation by reducing the 137 pathogen's ability to attack introduced commensals. We modified our model to consider 138 a scenario where a damage limitation therapy (of treatment intensity x) is given 139 alongside manipulation of the microbiome. This modification of our model shows that 140 using damage limitation therapy in combination with microbiome manipulation 7 expands the range of conditions where the pathogen can be eradicated, and can offset 142 increases in mortality owing to increased selection for virulence factor production by 143 decreasing the virulence factors effects on the host (Fig. 4) . 144
Advances in microbiome sequencing and techniques to discover interactions among 145 microbes from sequence data offer the hope of allowing us to engineer the human 146 microbiota to repel or clear invading pathogens 27 . While this is a highly promising 147 therapeutic avenue, just as with other forms of antimicrobial treatment there is the 148 potential for pathogens to evolve resistance to our interventions. Our results show that 149 one potential pathogen response to microbiome manipulation is to upregulate its 150 arsenal of virulence factors that it uses to clear commensals. This leads to a scenario 151 analogous to the 'double--edged sword' effects of antimicrobial drug dosing 28 , where 152 higher doses of drugs maximise selection for resistance, but also reduce the supply of 153 resistance mutations, reduce prevalence, and increase the chances of pathogen 154 eradication. The overarching lesson from this problem has been that we need to 155 carefully consider the evolutionary responses of pathogens when designing treatment 156 strategies 28 . Given that an expected evolutionary response of pathogens to increases in 157 competition is to increase their virulence, it is critical to heed this lesson when designing 158 manipulations of the microbiome. 159
Where microbiome manipulation is not efficacious enough to achieve pathogen 160 eradication our results suggest the use of co--therapies that reduce the impact of 161 pathogen virulence factors. These 'damage limitation' therapies are the subject of much 162 current interest as they are expected to show less resistance evolution than traditional 163 antimicrobials 8,25 . Our results suggest that by reducing the impact of pathogen virulence 164 factors on commensals, damage limitation therapies could show a strong synergy with 165 microbiome manipulation and help achieve pathogen eradication. 166
Microbiome manipulation has already been successfully deployed to treat recurrent C. Within--host model. We model the dynamics of the pathogen and introduced commensal 190 using the replicator equation 31 , with the dynamics of the within--host frequency of the 191 pathogen, P, given by 192
where ! = − − 1 − and ! = − are the growth rates of the pathogen 193 and commensal, respectively. Evaluating P at = 0, and assuming b > c, we find 194 stable equilibria at P = 0 and P = 1, and an unstable equilibrium given in equation 1. 195
Epidemiological model. We use the simplest scenario of a susceptible--infected 196 epidemiological model to model the spread of strains with different levels of investment 197 in virulence factor production. We assume that host deaths are immediately replaced by 198 births and that treatment--induced clearance is proportional to the location of the 199 threshold for invasion by the introduced commensal 12,32 . Using these assumptions the 200 epidemiological dynamics are given by 201
where N, is the host population density, I is the density of infected hosts, S = N -I is the 202 density of susceptible hosts, β is a transmission constant, γ is the infection clearance 203 rate, δ is the baseline host death rate, τ is the treatment rate, and virulence factor 204 production increases the host death rate by v. From this we can write the 'reproductive 205 number' (number of secondary infections caused when rare) 33 by evaluating the ratio of 206 transmission and loss rates when the pathogen is rare ( → 0) giving equation 2. The ES 207 level of virulence factor production ( * ) by finding the value of v that maximises R0(v), 208
giving equation 3, which shows that the ES virulence factor production ( * ) increases 209 with increased treatment rates (τ).
10
To evaluate the impact of microbiome manipulation on the long--term epidemiology of 211 the pathogen we evaluate the pathogen R0 at evolutionary equilibrium ( = * ), giving 212
which must be greater than 1 for the pathogen to avoid eradication. This R0 corresponds 213 to an equilibrium pathogen prevalence of
We can see from equation 7 that pathogen prevalence, Q * , declines with increasing rates 215 of treatment with microbiome manipulation, τ, with the pathogen being eradicated at 216 sufficiently high treatment rates. 217
Given that introducing competitors in the microbiome selects for higher virulence but 218 also reduces the prevalence of infection what is the impact of microbiome manipulation 219 on the total disease induced mortality? The total disease induced mortality at 220 evolutionary equilibrium is given by * = * + * , which is
Analysing equation 8, and from Fig. 2d , we can see that the then the total disease 222 induced mortality can increase with τ, though must decline with τ at higher levels as the 223 pathogen approaches eradication. This result shows that the evolutionary risks of 224 microbiome manipulation must be carefully considered -if treatment is not sufficiently 225 aggressive it may result in increased disease induced mortality owing to evolutionary 226 increases in virulence. 227
Combining microbiome manipulation and damage limitation. We consider a damage 228 limitation therapy, of treatment intensity x, used in combination with microbiome 229 manipulation. By disrupting the effects of the virulence factor the damage limitation 230 therapy reduces both the pathogen's effect on introduced commensals and damage to 231 the host. Weighting these effects by damage limitation efficacy the pathogen R0 is now 232
and the ES virulence is
Here we can see that damage limitation therapy has a non--monotonic (humped) effect 234 on ES virulence. Again we evaluate the pathogen R0 at evolutionary equilibrium ( = 235 * ), giving 236
and corresponding to an equilibrium prevalence of 237 * = 1 −
which decreases with x whenever > − 1 + , meaning damage limitation 238 therapy helps reduced pathogen prevalence by reducing the pathogen's ability to attack 239 the commensal competitors via its virulence factors. The total disease induced mortality 240 at evolutionary equilibrium is given by 241
the full expression for which can be calculated using equations 10 and 12. Note that 242 though damage limitation increases the ES virulence factor expression, this is offset by 243 damage limitation reducing the efficacy of the virulence factor; meaning that the total 244 disease induced mortality decreases with damage limitation therapy. Note however, that 245 this only holds as long as damage limitation therapy is continued to be used, ceasing use 246 while the pathogen is still at appreciable prevalence may increase mortality rates 8 . 247
Stochastic simulations of evolutionary rescue. To simulate the stochastic dynamics of 248 the evolution of virulence factor expression in response to microbiome manipulation 249 treatment we simulated our epidemiological model using the Gillespie algorithm 34 . Our 250 model consists of a finite population of N hosts, which can be infected with strains with 251 differing levels of virulence factor production. The rates of transmission, clearance of 252 infection, and host death (immediately replaced by birth of an uninfected host) are 253 calculated for each infection as per equation 5. In addition to these processes the strain 254 in each infection can mutate with mutation rate µ, in which case its virulence factor 255 expression has a value added to it from a normal distribution with mean 0 and variance 256 
